Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion

Molecular and Cellular Endocrinology

Volumn 355, Issue 1, 2012, Pages 106-113

  Cuny, Thomas ^a,b   Mohamed, Amira ^a   Graillon, Thomas ^a,c   Roche, Catherine ^a   Defilles, Céline ^a   Germanetti, Anne Laure ^d   Couderc, Bettina ^e   Figarella Branger, Dominique ^c   Enjalbert, Alain ^a,d   Barlier, Anne ^a,d   Saveanu, Alexandru ^a,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Department of Endocrinology   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Dopamine agonist; Dopastatin; Pituitary adenoma; Prolactinoma; Somatostatin receptor

Indexed keywords

BIM 23A760; CABERGOLINE; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; OCTREOTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE 2 RECEPTOR GENE; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; RECEPTOR GENE; SOMATOSTATIN RECEPTOR 2 GENE;

ADENOVIRIDAE; ADOLESCENT; ADULT; DOPAMINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; GENETIC VECTORS; HUMANS; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; PRIMARY CELL CULTURE; PROLACTIN; PROLACTINOMA; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TRANSFECTION;

EID: 84858748136     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.01.026     Document Type: Article

References (36)

1. Acunzo J., Thirion S., Roche C., Saveanu A., Gunz G., Germanetti A.L., Couderc B., Cohen R., Figarella-Branger D., Dufour H., Brue T., Enjalbert A., Barlier A. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res. 2008, 68:10163-10170.
2. Baragli A., Alturaihi H., Watt H.L., Abdallah A., Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007, 19:2304-2316.
3. Ben-Shlomo A., Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab. 2010, 21:123-133.
4. de Bruin, C., van der Hoek, J., Waaijers, M., van Koetsveld, P.M., Dong, J., Culler, M.D., Themmen, A.P., Van der Lely, A.J., Lamberts, S.W., Hofland, L.J., 2008. Functional characterization of the dopamine somatostatin chimeric molecule BIM-23A760. In: 13th Congress of the European Neuroendocrine Association, Antalya, Turkey, pp. OC5.2.
5. Bulenger S., Marullo S., Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 2005, 26:131-137.
6. Caccavelli L., Feron F., Morange I., Rouer E., Benarous R., Dewailly D., Jaquet P., Kordon C., Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994, 60:314-322.
7. Caccavelli L., Morange-Ramos I., Kordon C., Jaquet P., Enjalbert A. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J. Neuroendocrinol. 1996, 8:737-746.
8. Colao A., di Sarno A., Pivonello R., di Somma C., Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert. Opin. Investig. Drugs 2002, 11:787-800.
9. Colao A., Auriemma R.S., Lombardi G., Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 2011, 32:247-271.
10. Delgrange E., Daems T., Verhelst J., Abs R., Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 2009, 160:747-752.
11. Duran-Prado M., Malagon M.M., Gracia-Navarro F., Castano J.P. Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol. 2008, 286:63-68.
12. Feelders R.A., de Bruin C., Pereira A.M., Romijn J.A., Netea-Maier R.T., Hermus A.R., Zelissen P.M., van Heerebeek R., de Jong F.H., van der Lely A.J., de Herder W.W., Hofland L.J., Lamberts S.W. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Engl. J. Med. 2010, 362:1846-1848.
13. Fernandez A., Brada M., Zabuliene L., Karavitaki N., Wass J.A. Radiation-induced hypopituitarism. Endocr. Relat. Cancer 2009, 16:733-772.
14. Florio T., Barbieri F., Spaziante R., Zona G., Hofland L.J., van Koetsveld P.M., Feelders R.A., Stalla G.K., Theodoropoulou M., Culler M.D., Dong J., Taylor J.E., Moreau J.P., Saveanu A., Gunz G., Dufour H., Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 2008, 15:583-596.
15. Fusco A., Gunz G., Jaquet P., Dufour H., Germanetti A.L., Culler M.D., Barlier A., Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur. J. Endocrinol. 2008, 158:595-603.
16. Grant M., Alturaihi H., Jaquet P., Collier B., Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 2008, 22:2278-2292.
17. Han Y., Moreira I.S., Urizar E., Weinstein H., Javitch J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 2009, 5:688-695.
18. Hofland L.J., Feelders R.A., de Herder W.W., Lamberts S.W. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol. Cell. Endocrinol. 2010, 326:89-98.
19. Jaquet P., Gunz G., Grisoli F. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res. 1985, 22:153-163.
20. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab. 1999, 84:3268-3276.
21. Jaquet P., Gunz G., Saveanu A., Barlier A., Dufour H., Taylor J., Dong J., Kim S., Moreau J.P., Culler M.D. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest. 2005, 28:21-27.
22. Klibanski A. Clinical practice: Prolactinomas. N. Engl. J. Med. 2010, 362:1219-1226.
23. Lahlou H., Guillermet J., Hortala M., Vernejoul F., Pyronnet S., Bousquet C., Susini C. Molecular signaling of somatostatin receptors. Ann. N Y Acad. Sci. 2004, 1014:121-131.
24. Lamberts S.W., Zweens M., Klijn J.G., van Vroonhoven C.C., Stefanko S.Z., Del Pozo E. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 1986, 25:201-212.
25. Martin R.E., Green L.G., Guba W., Kratochwil N., Christ A. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J. Med. Chem. 2007, 50:6291-6294.
26. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., Wass J.A. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:273-288.
27. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
28. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005, 8:43-52.
29. Moyes V.J., Metcalfe K.A., Drake W.M. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 2008, 159:541-545.
30. Rocheville M., Lange D.C., Kumar U., Sasi R., Patel R.C., Patel Y.C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 2000, 275:7862-7869.
31. Saveanu A., Lavaque E., Gunz G., Barlier A., Kim S., Taylor J.E., Culler M.D., Enjalbert A., Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 2002, 87:5545-5552.
32. Saveanu A., Jaquet P., Brue T., Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol. Cell. Endocrinol. 2008, 286:206-213.
33. Sharif N., Gendron L., Wowchuk J., Sarret P., Mazella J., Beaudet A., Stroh T. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007, 148:2095-2105.
34. Stefaneanu L., Kovacs K., Horvath E., Buchfelder M., Fahlbusch R., Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001, 14:329-336.
35. Thodou E., Kontogeorgos G., Theodossiou D., Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J. Clin. Pathol. 2006, 59:274-279.
36. Tulipano G., Bonfanti C., Milani G., Billeci B., Bollati A., Cozzi R., Maira G., Murphy W.A., Poiesi C., Turazzi S., Giustina A. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001, 73:344-351.